PTCT
VENTE TOTALE: 16 126 titres (~1 230 782,44 $ US)
- Insiders
- Klein Matthew B., Smith Mary L.
- Total bought
- —
- Total sold
- $1,230,782
- Last activity
- 2026-08-04
- Last synced
-
2026-08-10 09:45:27
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Neutral signal Scored 2026-08-07
PTCT shows a compelling fundamental turnaround with strong profitability (net margin ~39%) and solid liquidity/trend scores (75/85), but the event-driven layer is decisively bearish: heavy insider selling of $1.23M+…
The first sentence of the analysis written for PTCT on 2026-08-07 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 95.9% | 92.9% | 93.0% | 93.6% | 94.0% | |
| Ebit Margin | 49.0% | -24.3% | -60.5% | -71.1% | -80.3% | |
| Ebitda Margin | 51.3% | -14.9% | -35.2% | -52.6% | -68.4% | |
| Operating Profit Margin | 49.5% | -37.5% | -46.9% | -64.0% | -69.5% | |
| Pretax Profit Margin | 40.3% | -45.0% | -74.2% | -84.1% | -96.2% | |
| Continuous Operations Profit Margin | 39.4% | -45.0% | -66.8% | -80.0% | -97.3% | |
| Net Profit Margin | 39.4% | -45.0% | -66.8% | -80.0% | -97.3% | |
| Bottom Line Profit Margin | 39.4% | -45.0% | -66.8% | -80.0% | -97.3% | |
| Current Ratio | 2.348 | 2.350 | 2.021 | 1.708 | 1.874 | |
| Quick Ratio | 2.266 | 2.310 | 1.970 | 1.654 | 1.843 | |
| Solvency Ratio | 0.232 | -0.103 | -0.144 | -0.210 | -0.237 | |
| Cash Ratio | 1.017 | 1.342 | 0.985 | 0.689 | 0.372 | |
| Price To Earnings Ratio | 8.853 | -9.543 | -3.293 | -4.900 | -5.361 | |
| Price To Earnings Growth Ratio | -0.031 | 0.219 | -0.442 | -1.011 | -0.451 | |
| Forward Price To Earnings Growth Ratio | -0.031 | 0.219 | -0.442 | -1.011 | -0.451 | |
| Price To Earnings Diluted Ratio | 9.763 | -9.543 | -3.293 | -4.900 | -5.361 | |
| Price To Earnings Diluted Growth Ratio | -0.037 | 0.219 | -0.442 | -1.011 | -0.451 | |
| Price To Book Ratio | -29.425 | -3.159 | -2.520 | -7.888 | 1,951.792 | |
| Price To Sales Ratio | 3.491 | 4.300 | 2.199 | 3.918 | 5.211 | |
| Price To Free Cash Flow Ratio | 14.693 | -19.066 | -7.392 | -5.378 | -8.337 | |
| Price To Operating Cash Flow Ratio | 8.495 | -32.211 | -13.020 | -7.677 | -11.167 | |
| Debt To Assets Ratio | 0.934 | 1.449 | 1.176 | 0.857 | 0.655 | |
| Debt To Equity Ratio | -13.185 | -2.250 | -2.723 | -4.211 | 882.729 | |
| Debt To Capital Ratio | 1.082 | 1.800 | 1.580 | 1.311 | 0.999 | |
| Long Term Debt To Capital Ratio | 1.113 | 2.086 | 1.754 | 1.381 | 0.998 | |
| Financial Leverage Ratio | -14.119 | -1.553 | -2.316 | -4.914 | 1,347.744 | |
| Working Capital Turnover Ratio | 1.656 | 1.152 | 2.077 | 1.908 | 0.770 | |
| Operating Cash Flow Ratio | 0.734 | -0.185 | -0.263 | -0.878 | -0.493 | |
| Operating Cash Flow Sales Ratio | 0.411 | -0.133 | -0.169 | -0.510 | -0.467 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.578 | 1.689 | 1.761 | 1.427 | 1.340 | |
| Debt Service Coverage Ratio | 1.210 | -0.284 | -0.806 | -2.081 | -1.268 | |
| Interest Coverage Ratio | 5.626 | -1.812 | -3.402 | -4.924 | -4.353 | |
| Short Term Operating Cash Flow Coverage Ratio | 1.249 | -0.418 | -0.815 | -4.943 | -1.204 | |
| Operating Cash Flow Coverage Ratio | 0.263 | -0.044 | -0.071 | -0.244 | -0.198 | |
| Capital Expenditure Coverage Ratio | 2.371 | -1.450 | -1.313 | -2.339 | -2.945 | |
| Dividend Paid And Capex Coverage Ratio | 2.371 | -1.450 | -1.313 | -2.339 | -2.945 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 8.746 | -42.836 | -11.194 | -10.657 | -10.555 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 95.9% | ▲3.0% | ▲2.0% |
| Ebit Margin | 49.0% | ▲73.4% | ▲86.5% |
| Ebitda Margin | 51.3% | ▲66.2% | ▲75.3% |
| Operating Profit Margin | 49.5% | ▲87.0% | ▲83.2% |
| Pretax Profit Margin | 40.2% | ▲85.3% | ▲92.1% |
| Continuous Operations Profit Margin | 39.4% | ▲84.5% | ▲89.4% |
| Net Profit Margin | 39.4% | ▲84.5% | ▲89.4% |
| Bottom Line Profit Margin | 39.4% | ▲84.5% | ▲89.4% |
| Current Ratio | 2.348 | ▼-0.002 | ▲0.288 |
| Quick Ratio | 2.266 | ▼-0.045 | ▲0.257 |
| Solvency Ratio | 0.232 | ▲0.335 | ▲0.325 |
| Cash Ratio | 1.017 | ▼-0.325 | ▲0.136 |
| Price To Earnings Ratio | 8.853 | ▲18.396 | ▲11.702 |
| Price To Earnings Growth Ratio | -0.032 | ▼-0.251 | ▲0.312 |
| Forward Price To Earnings Growth Ratio | -0.032 | ▼-0.251 | ▲0.312 |
| Price To Earnings Diluted Ratio | 9.764 | ▲19.307 | ▲12.430 |
| Price To Earnings Diluted Growth Ratio | -0.037 | ▼-0.256 | ▲0.307 |
| Price To Book Ratio | -29.425 | ▼-26.267 | ▼-411.185 |
| Price To Sales Ratio | 3.491 | ▼-0.809 | ▼-0.333 |
| Price To Free Cash Flow Ratio | 14.693 | ▲33.759 | ▲19.789 |
| Price To Operating Cash Flow Ratio | 8.495 | ▲40.706 | ▲19.611 |
| Debt To Assets Ratio | 0.934 | ▼-0.515 | ▼-0.080 |
| Debt To Equity Ratio | -13.185 | ▼-10.935 | ▼-185.257 |
| Debt To Capital Ratio | 1.082 | ▼-0.718 | ▼-0.272 |
| Long Term Debt To Capital Ratio | 1.113 | ▼-0.973 | ▼-0.354 |
| Financial Leverage Ratio | -14.119 | ▼-12.566 | ▼-279.087 |
| Working Capital Turnover Ratio | 1.656 | ▲0.504 | ▲0.143 |
| Operating Cash Flow Ratio | 0.734 | ▲0.920 | ▲0.951 |
| Operating Cash Flow Sales Ratio | 0.411 | ▲0.544 | ▲0.585 |
| Free Cash Flow Operating Cash Flow Ratio | 0.578 | ▼-1.111 | ▼-0.781 |
| Debt Service Coverage Ratio | 1.210 | ▲1.494 | ▲1.856 |
| Interest Coverage Ratio | 5.626 | ▲7.438 | ▲7.399 |
| Short Term Operating Cash Flow Coverage Ratio | 1.248 | ▲1.666 | ▲2.475 |
| Operating Cash Flow Coverage Ratio | 0.263 | ▲0.306 | ▲0.322 |
| Capital Expenditure Coverage Ratio | 2.371 | ▲3.821 | ▲3.506 |
| Dividend Paid And Capex Coverage Ratio | 2.371 | ▲3.821 | ▲3.506 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 8.746 | ▲51.582 | ▲22.046 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $6.04B | $3.47B | $2.06B | $2.74B | $2.81B | |
| Enterprise value | $7.76B | $5.16B | $3.70B | $3.92B | $3.89B | |
| EV / Sales | 4.49x | 6.40x | 3.94x | 5.61x | 7.22x | |
| EV / Op. cash flow | 10.92x | -47.92x | -23.34x | -10.99x | -15.46x | |
| EV / Free cash flow | 18.88x | -28.36x | -13.25x | -7.70x | -11.54x | |
| EV / EBITDA | 8.75x | -42.84x | -11.19x | -10.66x | -10.55x | |
| Net debt / EBITDA | 1.94x | -14.04x | -4.95x | -3.21x | -2.93x | |
| Current ratio | 2.35x | 2.35x | 2.02x | 1.71x | 1.87x | |
| Income quality | 1.04x | 0.30x | 0.25x | 0.64x | 0.48x | |
| Graham net-net | -$12 | -$20 | -$23 | -$21 | -$15 | |
| Tax burden | 98.0% | 100.0% | 90.0% | 95.2% | 101.1% | |
| Interest burden | 82.1% | 185.1% | 122.8% | 118.3% | 119.9% | |
| Working capital | $1.31B | $784.5M | $615.5M | $287.5M | $445.0M | |
| Invested capital | $1.91B | $1.10B | $1.26B | $1.25B | $1.38B | |
| Return on assets | 23.5% | -21.3% | -33.1% | -32.8% | -27.0% | |
| Operating ROA | 37.2% | -16.8% | -24.4% | -24.6% | -18.1% | |
| Return on tangible assets | 28.1% | -24.2% | -43.7% | -60.9% | -46.3% | |
| Return on equity | -332.5% | 33.1% | 76.6% | 161.1% | -36432.6% | |
| Return on invested capital | 33.4% | -21.7% | -26.3% | -30.8% | -22.7% | |
| Return on capital employed | 44.4% | -26.9% | -34.0% | -34.4% | -26.2% | |
| Earnings yield | 11.3% | -10.5% | -30.4% | -20.4% | -18.7% | |
| Free cash flow yield | 6.8% | -5.2% | -13.5% | -18.6% | -12.0% | |
| Capex / Op. cash flow | 42.2% | -68.9% | -76.1% | -42.7% | -34.0% | |
| Capex / Depreciation | 772.9% | 98.1% | 51.0% | 118.3% | 133.1% | |
| Capex / Sales | 17.3% | 9.2% | 12.9% | 21.8% | 15.8% | |
| SG&A / Sales | 20.1% | 37.3% | 35.5% | 46.7% | 53.1% | |
| R&D / Sales | 26.3% | 66.2% | 71.1% | 93.2% | 100.4% | |
| Stock comp / Sales | 4.3% | 9.2% | 14.0% | 15.8% | 19.2% | |
| Intangibles / Total assets | 16.3% | 11.8% | 24.4% | 46.2% | 41.6% | |
| Days sales outstanding | 38d | 72d | 63d | 81d | 75d | |
| Days payables outstanding | 231d | 110d | 34d | 223d | 260d | |
| Operating cycle | 443d | 219d | 233d | 259d | 254d | |
| Cash conversion cycle | 212d | 109d | 199d | 37d | -6d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+74.2%EV / Sales ▼-29.9%EV / EBITDA ▲+120.4%EV / Op. cash flow ▲+58.834Earnings yield ▲+0.218
Profitability
Return on equity ▼-3.656Return on assets ▲+0.449Return on invested capital ▲+0.551Return on capital employed ▲+0.713Operating ROA ▲+0.540Income quality ▲+0.745Tax burden ▼-0.021
Efficiency
Days sales outstanding ▼-33.428Days payables outstanding ▲+121.534Operating cycle ▲+224.224Cash conversion cycle ▲+102.690Capex / Sales ▲+0.081R&D / Sales ▼-0.399
Balance-sheet strength
Current ratio ▼-0.002Net debt / EBITDA ▲+15.981Working capital ▲+520971000.000Invested capital ▲+808699000.000Intangibles / Total assets ▲+0.045
Change over 5 years
Valuation
Market cap ▲+115.3%EV / Sales ▼-37.8%EV / EBITDA ▲+182.9%EV / Op. cash flow ▲+26.380Earnings yield ▲+0.300
Profitability
Return on equity ▲+361.001Return on assets ▲+0.506Return on invested capital ▲+0.561Return on capital employed ▲+0.706Operating ROA ▲+0.553Income quality ▲+0.562Tax burden ▼-0.031
Efficiency
Days sales outstanding ▼-36.550Days payables outstanding ▼-28.673Operating cycle ▲+189.572Cash conversion cycle ▲+218.246Capex / Sales ▲+0.015R&D / Sales ▼-0.741
Balance-sheet strength
Current ratio ▲+0.474Net debt / EBITDA ▲+4.873Working capital ▲+860501000.000Invested capital ▲+529831000.000Intangibles / Total assets ▼-0.254
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-08-04 PTC Therapeutics (PTCT) Loses 20.3% in 4 Weeks, Here''s Why a Trend Reversal May be Around the Corner PTC Therapeutics (PTCT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- 2026-07-31 PTC Therapeutics (PTCT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates Although the revenue and EPS for PTC Therapeutics (PTCT) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 2026-07-30 PTC Therapeutics, Inc. (PTCT) Q2 2026 Earnings Call Transcript PTC Therapeutics, Inc. (PTCT) Q2 2026 Earnings Call Transcript
- 2026-07-30 PTC Therapeutics (PTCT) Beats Q2 Earnings and Revenue Estimates PTC Therapeutics (PTCT) came out with quarterly earnings of $0.92 per share, beating the Zacks Consensus Estimate of a loss of $0.17 per share. This compares to a loss of $0.83 per share a year ago.
- 2026-07-30 PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results – Robust Q2 performance with total revenue of $361 million, including $239 million of product revenue – – Full-year 2026 expected total revenue increased to $1.18 to $1.28 billion, with full-year product revenue guidance raised to $850 to $950 million – – Sephience™ (sepiapterin) Q2 2026 revenue of $151 million, with continued broad uptake and geographical expansion – – Strong cash position of $2.2 billion as of June 30, 2026 – WARREN, N.J., July 30, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the second quarter ended June 30, 2026.
- 2026-07-25 PTC Therapeutics, Inc. $PTCT Shares Purchased by Fifth Third Bancorp Fifth Third Bancorp increased its position in shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) by 12,362.1% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 17,447 shares of the biopharmaceutical company''s stock after acquiring an additional 17,307 shares
- 2026-07-23 Hamilton Lane Board Elects Michael Schmertzler as New Independent Director CONSHOHOCKEN, Pa., July 23, 2026 /PRNewswire/ -- Leading private markets investment management firm Hamilton Lane (Nasdaq: HLNE) announced that its Board of Directors elected Michael Schmertzler as a new independent director, effective July 22, 2026.
- 2026-07-22 PTC Therapeutics, Inc. $PTCT Shares Purchased by Bessemer Group Inc. Bessemer Group Inc. boosted its position in shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) by 21,814.1% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 52,813 shares of the biopharmaceutical company''s stock after buying an additional 52,572 shares during the quarter. Bessemer
- 2026-07-16 PTC Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, July 30, 2026 WARREN, N.J., July 16, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its second quarter 2026 financial results and provide an update on the company''s business and outlook on Thursday, July 30, 2026, at 4:30 p.m.
- 2026-07-13 What This PTC Therapeutics Insider Sale Means as Product Revenue Hit $226 Million The transaction generated $222,376 in gross proceeds, realized through the exercise of 2,464 options at $46.54 and their immediate sale at a weighted average price of $90.25. The disposition represented 4% of the insider''s direct common stock holdings.